Feng Bihua, Tse Heong W, Skifter Donald A, Morley Richard, Jane David E, Monaghan Daniel T
Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE 68198-6260, U.S.A.
Br J Pharmacol. 2004 Feb;141(3):508-16. doi: 10.1038/sj.bjp.0705644. Epub 2004 Jan 12.
(2S*,3R*)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid (PBPD) is a moderate affinity, competitive N-methyl-d-aspartate (NMDA) receptor antagonist with an atypical pattern of selectivity among NMDA receptor 2 subunit (NR2) subunits. We now describe the activity of several derivatives of PBPD tested at both rat brain NMDA receptors using l-[3H]-glutamate binding assays and at recombinant receptors expressed in Xenopus oocytes. Substituting various branched ring structures for the biphenyl group of PBPD reduced NMDA receptor activity. However, substituting linearly arranged ring structures - fluorenone or phenanthrene groups - retained or enhanced activity. Relative to PBPD, the phenanthrene derivative (2S*, 3R*)-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid (PPDA) displayed a 30- to 78-fold increase in affinity for native NMDA receptors. At recombinant receptors, PPDA displayed a 16-fold (NR2B) to 94-fold (NR2C) increase in affinity over PBPD. Replacement of the biphenyl group of PBPD with a 9-oxofluorene ring system resulted in small changes in receptor affinity and subtype selectivity. 2'-Bromo substitution on the biphenyl group of PBPD reduced antagonist affinity 3- to 5-fold at NR2A-, NR2B- and NR2D-containing receptors, but had little effect on NR2C-containing receptors. In contrast, 4'-fluoro substitution of the biphenyl ring of PBPD selectively increased NR2A affinity. The aromatic rings of PBPD and PPDA increase antagonist affinity and appear to interact with a region of the NMDA receptor displaying subunit heterogeneity. PPDA is the most potent and selective NR2C/NR2D-preferring antagonist yet reported and thus may be useful in defining NR2C/NR2D function and developing related antagonists with improved NMDA receptor subtype selectivity. British Journal of Pharmacology (2004) 141, 508-516. doi:10.1038/sj.bjp.0705644
(2S*,3R*)-1-(联苯-4-羰基)哌嗪-2,3-二羧酸(PBPD)是一种具有中等亲和力的竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,在NMDA受体2亚基(NR2)中具有非典型的选择性模式。我们现在描述了几种PBPD衍生物在大鼠脑NMDA受体上使用l-[3H]-谷氨酸结合试验以及在非洲爪蟾卵母细胞中表达的重组受体上的活性。用各种支链环状结构取代PBPD的联苯基团会降低NMDA受体活性。然而,用线性排列的环状结构——芴酮或菲基团——取代则保留或增强了活性。相对于PBPD,菲衍生物(2S*, 3R*)-1-(菲-2-羰基)哌嗪-2,3-二羧酸(PPDA)对天然NMDA受体的亲和力增加了30至78倍。在重组受体上,PPDA相对于PBPD的亲和力增加了16倍(NR2B)至94倍(NR2C)。用9-氧代芴环系统取代PBPD的联苯基团导致受体亲和力和亚型选择性有微小变化。PBPD联苯基团上的2'-溴取代使含NR2A、NR2B和NR2D的受体的拮抗剂亲和力降低3至5倍,但对含NR2C的受体影响很小。相比之下,PBPD联苯环上的4'-氟取代选择性地增加了NR2A亲和力。PBPD和PPDA的芳香环增加了拮抗剂亲和力,并且似乎与显示亚基异质性的NMDA受体区域相互作用。PPDA是迄今报道的最有效且最具选择性的偏向NR2C/NR2D的拮抗剂,因此可能有助于确定NR2C/NR2D的功能以及开发具有改善的NMDA受体亚型选择性的相关拮抗剂。《英国药理学期刊》(2004年)141卷,508 - 516页。doi:10.1038/sj.bjp.0705644